Loading...
•
Dec 31, 2025
Dyne Therapeutics Q4 2025 Earnings Report
Dyne Therapeutics reported fourth quarter 2025 financial results with increased R&D spending and a wider net loss year-over-year.
Key Takeaways
For Q4 2025, Dyne reported a net loss of 111955000, driven by research and development expenses of 95431000 and general and administrative expenses of 20698000. The company ended the year with 1110562000 in cash, cash equivalents and marketable securities, supporting runway into Q1 2028.
Net loss for Q4 2025 was 111955000 compared to 89540000 in Q4 2024.
Research and development expenses increased to 95431000.
General and administrative expenses rose to 20698000.
Cash, cash equivalents and marketable securities totaled 1110562000 at year end.
Forward Guidance
Dyne expects its cash, cash equivalents and marketable securities as of December 31, 2025 to fund operations into the first quarter of 2028 while advancing its DMD and DM1 programs toward potential accelerated approvals.
Positive Outlook
- Year-end cash position of 1110562000.
- Expected cash runway into Q1 2028.
- Planned BLA submission for z-rostudirsen in Q2 2026.
- Potential U.S. launch of z-rostudirsen in Q1 2027.
- Phase 3 trials for z-rostudirsen and z-basivarsen expected to initiate in 2026.
Challenges Ahead
- Quarterly net loss of 111955000.
- R&D expenses increased year-over-year.
- G&A expenses increased year-over-year.
- No product revenue generated.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...